UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000001631
Receipt No. R000001963
Scientific Title Phase II study of a combination of CPT-11 and S-1 and bevacizumab in patients with metastatic colon cancer.
Date of disclosure of the study information 2009/01/14
Last modified on 2019/02/03

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Phase II study of a combination of CPT-11 and S-1 and bevacizumab in patients with metastatic colon cancer.
Acronym Phase II study of a combination of CPT-11 and S-1 and bevacizumab in patients with metastatic colon cancer.
Scientific Title Phase II study of a combination of CPT-11 and S-1 and bevacizumab in patients with metastatic colon cancer.
Scientific Title:Acronym Phase II study of a combination of CPT-11 and S-1 and bevacizumab in patients with metastatic colon cancer.
Region
Japan

Condition
Condition metastatic colorectal cancer
Classification by specialty
Hematology and clinical oncology Gastrointestinal surgery
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 The primary objective of this study was to explore the progression free survival (PFS), antitumor effect (response rate), overall survival (OS), time to treatment failure (TTF) and safety of these three drugs, which combined chemotherapy with CPT-11, S-1 and bevacizumab in patients with metastatic colorectal cancer.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1 Confirmatory
Trial characteristics_2 Pragmatic
Developmental phase Phase II

Assessment
Primary outcomes Progression Free Survival
Key secondary outcomes Response Rate
Overall survial
Time to Treatment Failure
Safety

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 We use three drugs (CPT-11, S-1, bevacizumab) for this trial. The treatment schedule of CPT-11 and bevacizumab are administrated on day 1 and day 15, and of S-1 is administrated between day1 and day 21. The dosage of CPT-11 are 75 mg/m2, and of S-1 are 65 mg (the dosage are calculated by body surface area), and of bevacizumab are 10 mg/kg.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
80 years-old >=
Gender Male and Female
Key inclusion criteria The eligibility criteria were as follows:1)2)3) histologically proven unresectable metastatic colorectal adenocarcinoma with assessable lesions; 4) previous first line chemotherapy containing oxaliplatine, and was progression disease or treatment failure; 5) at least 2 weeks must have elapsed since any prior chemotherapy; 6) prior radiation therapy are not done; 7) age 20-80 years patients; 8) Eastern Cooperative Oncology performance status (PS) 0-1; 9) survival period more than 3 months; 10) adequate organ function before fourteen days, defined as leukocyte count >4000-12000/mm3, platelet count >100000/mm3, neutrophil cell count >2000/mm3, hemoglobin >9.0 g/dl, serum transaminase (aspartate aminotransferase and alanine aminotransferase) <100/UI (in case of hepatic metastatic patients are at a physician's discretion), serum bilirubin level <1.5mg/dl, serum creatinine level <1.2mg/dl, estimated creatinine clearance level > 50ml/min (in case of woman, the value is 0.85 times); 9) the patients who can take oral drugs; 10) patients determined by electrocardiography within 28 days before entry, and allowed to enroll this trial by primary doctor; 11) and written informed consent from the patients; 12) the patients can eat
This study was approved by the ethics committees in each institution.
Key exclusion criteria The exclusion criteria were as follows; patients were not eligible for this study if; 1) they had undergone treatment with CPT-11 chemotherapy prior to this study, 2) had active double cancer; 3) had active infection disease (over 38.0C fever); 4) had gastrointestinal paralysis, bowel blockage or history within 1 year before entry; 5) had serious interstitial lung disease and lung fibrosis; 6) had water solubility diarrhea; 7) had diabetes mellitus which could not be controlled; 8) had hypertension which could not control with drug therapy; 9) had proteinuria > 2 plus 10) had serious complication (e.g. heart failure, hepatic failure, kidney failure); 11) had comorbid disease of cerebral vascular disorder or history within 1 year before entry; 12) were operated or performed dissected biopsy within 4 weeks before entry; 13) were bleeding tendency, coagulation disorder, abnormality of coagulation factor (INR>1.5) within 2 weeks before entry; 14) were administered antithrombotic within 10 days before entry; 15) were administered antiplatelet agent for chronic rheumatoid arthritis; 16) were administred flucytosine or atazanavir ; 17) were systemically-administered of steroids
; 18) Pregnant or lactating women, women who are capable of pregnancy or intend to get pregnant ; 19) had a previous serious medical illness or allergy for drugs ; 20) had brain metastasis or had treated for brain metastasis ; 21) had myelosuppression ; 22) had pleural effusion or abdominal dropsy which need therapy ; 23) had jaundice ; 24) except referred to above, physician in charge of this trial gave a diagnosis the patient who can not joint this trail for the safety.
Target sample size 35

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Katsuyoshi Hatakeyama
Organization Niigata University Medical & Dental Hospital
Division name President of a hospital
Zip code
Address 754, Asahimachi-dori, Chuo-ku, Niigata City 951-8520, Niigata Prefecture, JAPAN
TEL 025-223-6161
Email

Public contact
Name of contact person
1st name
Middle name
Last name Yasumasa Takii
Organization Niigata Cancer Center Hospital
Division name Surgery
Zip code
Address 2-15-3, Kawagishi-chou, Chuo-ku, Niigata City 951-8520, Niigata Prefecture, JAPAN
TEL 025-266-5111
Homepage URL
Email takii@niigata-cc.jp

Sponsor
Institute Niigata Colorectal cancer Chemotherapy Study Group (NCCSG)
Institute
Department

Funding Source
Organization None
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor Niigata Colorectal cancer Chemotherapy Study Group
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2009 Year 01 Month 14 Day

Related information
URL releasing protocol
Publication of results Published

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2008 Year 11 Month 26 Day
Date of IRB
Anticipated trial start date
2009 Year 01 Month 01 Day
Last follow-up date
2013 Year 01 Month 01 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2009 Year 01 Month 14 Day
Last modified on
2019 Year 02 Month 03 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001963

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.